RESUMO
Human adipose-derived stromal cells (hADSC) are a heterogeneous cell population that contains adult multipotent stem cells. Although it is well established that hADSC have skeletal potential in vivo in adult organisms, in vitro assays suggest further differentiation capacity, such as into glia. Thus, we propose that grafting hADSC into the embryo can provide them with a much more instructive microenvironment, allowing the human cells to adopt diverse fates or niches. Here, hADSC spheroids were grafted into either the presumptive presomitic mesoderm or the first branchial arch (BA1) regions of chick embryos. Cells were identified without previous manipulations via human-specific Alu probes, which allows efficient long-term tracing of heterogeneous primary cultures. When grafted into the trunk, in contrast to previous studies, hADSC were not found in chondrogenic or osteogenic territories up to E8. Surprisingly, 82.5% of the hADSC were associated with HNK1+ tissues, such as peripheral nerves. Human skin fibroblasts showed a smaller tropism for nerves. In line with other studies, hADSC also adopted perivascular locations. When grafted into the presumptive BA1, 74.6% of the cells were in the outflow tract, the final goal of cardiac neural crest cells, and were also associated with peripheral nerves. This is the first study showing that hADSC could adopt a perineural niche in vivo and were able to recognize cues for neural crest cell migration of the host. Therefore, we propose that xenografts of human cells into chick embryos can reveal novel behaviors of heterogeneous cell populations, such as response to migration cues.
RESUMO
Many advances have been taken on elucidating embryonic development and tissue homeostasis and repair by the use of experimental strategies that preserve the three-dimensional (3D) organization and allow quantitative analysis of images over time (four-dimensional). Ranging from the understanding about the relationship between blastomeres and the events that take place during gastrulation by the use of time-lapse imaging through 3D cultures that mimic organogenesis, the advances in this area are of critical value. The studies on embryonic development without disrupting the original architecture and the development of 3D organoid cultures pave a new avenue for unprecedented experimental advances that will positively impact the emergence of new treatments applying regenerative principles for both tissue repair and organ transplant.
Assuntos
Desenvolvimento Embrionário/fisiologia , Matriz Extracelular/fisiologia , Homeostase/fisiologia , Imageamento Tridimensional/métodos , Organogênese/fisiologia , Imagem com Lapso de Tempo/métodos , Humanos , Imageamento Tridimensional/tendências , Imagem com Lapso de Tempo/tendênciasRESUMO
OBJECTIVE: This study aimed at assessing the effects of autologous transendocardial transplantation of bone marrow mononuclear cells (ATTBMMC) on symptoms, exercise capacity, myocardial perfusion and contractility in patients with severe ischemic heart disease during a 6-month follow-up period. METHODS: This prospective study comprised 21 patients as follows: the first 14 patients forming the treated group, and the last 7 patients forming the control group. Initially, all patients underwent clinical and laboratory assessment, treadmill testing, echocardiography, myocardial scintigraphy, and 24-hour Holter. The bone marrow mononuclear cells (BMMC) were isolated, washed, and diluted in 0.9% saline solution for transendocardial injection in areas of viable myocardium in the treated group, (15 0.2-mL injections). All patients were reassessed in the end of 2 and 6 months of follow-up. RESULTS: The demographic data and other characteristics did not significantly differ between the groups in the initial evaluation. No major adverse events related to the ATTBMMC were observed. In the end of 6 months, a reduction in the ischemic area was observed on nuclear perfusion imaging (P=0.05), as was a significant improvement in symptoms, functional capacity, and left ventricular overall function. CONCLUSION: This study showed that transendocardial injections of BMMC are safe in human beings with ischemic heart disease associated with severe ventricular dysfunction. The effects observed in the short run were maintained up to the sixth month of follow-up.
Assuntos
Transplante de Medula Óssea , Tolerância ao Exercício/fisiologia , Isquemia Miocárdica/cirurgia , Estudos Epidemiológicos , Teste de Esforço , Feminino , Coração/diagnóstico por imagem , Humanos , Masculino , Pessoa de Meia-Idade , Contração Miocárdica , Isquemia Miocárdica/diagnóstico por imagem , Neovascularização Fisiológica , Cintilografia , Transplante AutólogoRESUMO
OBJETIVO: Este estudo tem por objetivo avaliar os efeitos, no seguimento de 6 meses, do transplante autólogo, transendocárdico, de células mononucleares da medula óssea (TACMMO), sobre os sintomas, capacidade de exercício, perfusão e contratilidade miocárdica nos portadores de cardiopatia isquêmica grave. MÉTODOS: Vinte e um pacientes foram incluídos neste estudo prospectivo (os 14 primeiros pacientes, grupo tratado; os 7 últimos pacientes, grupo controle). Inicialmente todos os indivíduos foram submetidos à avaliação clínica e laboratorial, teste ergométrico, ecocardiograma, cintilografia miocárdica e Holter de 24 horas. As CMMO foram isoladas, lavadas e diluídas em salina 0,9 por cento para injeção transendocárdica em áreas de miocárdio viável no grupo tratado, (15 injeções de 0,2 ml). Todos os pacientes foram reavaliados ao final de 2 e 6 meses de acompanhamento. RESULTADOS: Os dados demográficos e demais características não diferiram significativamente entre os grupos na avaliação inicial. Não foram observados eventos adversos maiores relacionados ao TACMMO. Ao final de 6 meses, houve redução da área isquêmica na imagem de perfusão nuclear (p=0,05) e melhora significativa dos sintomas, da capacidade funcional e da função global do ventrículo esquerdo. CONCLUSAO: Este estudo demonstra a segurança da realização de injeções transendocárdicas de CMMO em humanos com cardiopatia isquêmica associada a grave disfunção ventricular. Os efeitos observados em curto prazo foram mantidos até 6 meses de acompanhamento.